Alector, Inc. (NASDAQ:ALEC) Stock Position Lifted by Vontobel Holding Ltd.

Vontobel Holding Ltd. raised its holdings in shares of Alector, Inc. (NASDAQ:ALEC) by 127.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,000 shares of the company’s stock after acquiring an additional 14,000 shares during the period. Vontobel Holding Ltd.’s holdings in Alector were worth $47,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Apollon Wealth Management LLC acquired a new position in Alector in the 4th quarter worth about $47,000. SG Americas Securities LLC increased its stake in Alector by 27.9% in the fourth quarter. SG Americas Securities LLC now owns 39,334 shares of the company’s stock valued at $74,000 after acquiring an additional 8,581 shares during the period. Nordea Investment Management AB increased its stake in Alector by 5.1% in the fourth quarter. Nordea Investment Management AB now owns 165,713 shares of the company’s stock valued at $295,000 after acquiring an additional 7,971 shares during the period. JPMorgan Chase & Co. raised its position in Alector by 64.7% in the third quarter. JPMorgan Chase & Co. now owns 2,728,823 shares of the company’s stock worth $12,716,000 after purchasing an additional 1,072,298 shares in the last quarter. Finally, Barclays PLC lifted its stake in Alector by 132.4% during the third quarter. Barclays PLC now owns 176,800 shares of the company’s stock worth $824,000 after purchasing an additional 100,731 shares during the period. Institutional investors own 85.83% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alector in a research note on Tuesday, November 26th. HC Wainwright reduced their price objective on shares of Alector from $35.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, November 29th. Morgan Stanley lowered shares of Alector from an “equal weight” rating to an “underweight” rating and cut their price objective for the stock from $10.00 to $3.00 in a research report on Tuesday, November 26th. BTIG Research reduced their price objective on shares of Alector from $16.00 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, November 26th. Finally, Mizuho downgraded shares of Alector from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $9.00 to $2.50 in a research note on Tuesday, December 17th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $3.75.

Alector Trading Up 0.5 %

ALEC stock opened at $1.87 on Friday. The firm has a 50-day moving average price of $1.79 and a 200-day moving average price of $3.61. Alector, Inc. has a 12 month low of $1.55 and a 12 month high of $7.58. The stock has a market capitalization of $183.13 million, a P/E ratio of -1.10 and a beta of 0.61.

Insider Buying and Selling

In related news, CEO Arnon Rosenthal sold 52,172 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $2.52, for a total transaction of $131,473.44. Following the sale, the chief executive officer now owns 2,507,074 shares in the company, valued at $6,317,826.48. The trade was a 2.04 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Sara Kenkare-Mitra sold 26,500 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $2.52, for a total value of $66,780.00. Following the completion of the transaction, the insider now directly owns 565,215 shares of the company’s stock, valued at approximately $1,424,341.80. The trade was a 4.48 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 95,161 shares of company stock worth $239,806 in the last three months. 9.10% of the stock is owned by corporate insiders.

Alector Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.